These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 23188129

  • 1. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues.
    Lynch JJ, Regan CP, Beatch GN, Gleim GW, Morabito CJ.
    J Cardiovasc Pharmacol; 2013 Mar; 61(3):226-32. PubMed ID: 23188129
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model.
    Allison B, Yang Y, Pourrier M, Gibson JK.
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):463-8. PubMed ID: 21283020
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C, Li J, Schweizer PA, Katus HA, Thomas D.
    Eur J Pharmacol; 2014 Feb 05; 724():51-7. PubMed ID: 24374008
    [Abstract] [Full Text] [Related]

  • 4. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts.
    van Middendorp LB, Strik M, Houthuizen P, Kuiper M, Maessen JG, Auricchio A, Prinzen FW.
    Europace; 2014 Aug 05; 16(8):1249-56. PubMed ID: 24481779
    [Abstract] [Full Text] [Related]

  • 5. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
    Seyler C, Schweizer PA, Zitron E, Katus HA, Thomas D.
    Biochem Biophys Res Commun; 2014 Aug 29; 451(3):415-20. PubMed ID: 25108155
    [Abstract] [Full Text] [Related]

  • 6. Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts.
    van Middendorp LB, Strik M, Houthuizen P, Kuiper M, Maessen JG, Auricchio A, Prinzen FW.
    J Cardiovasc Pharmacol; 2014 Jan 29; 63(1):25-32. PubMed ID: 24084224
    [Abstract] [Full Text] [Related]

  • 7. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS, Calzadilla SV, Diemer MJ, Hartman JC, Reynolds RD.
    J Pharmacol Exp Ther; 1987 Dec 29; 243(3):1225-34. PubMed ID: 3694532
    [Abstract] [Full Text] [Related]

  • 8. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs.
    Bechard J, Gibson JK, Killingsworth CR, Wheeler JJ, Schneidkraut MJ, Huang J, Ideker RE, McAfee DA.
    J Cardiovasc Pharmacol; 2011 Mar 29; 57(3):302-7. PubMed ID: 21266917
    [Abstract] [Full Text] [Related]

  • 9. Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria.
    van Hunnik A, Nasrallah H, Lau DH, Kuiper M, Verheule S, Schotten U.
    Europace; 2018 Jan 01; 20(1):140-148. PubMed ID: 28449044
    [Abstract] [Full Text] [Related]

  • 10. Atrial-selective antiarrhythmic activity by vernakalant fact or fiction?
    Christ T.
    J Cardiovasc Pharmacol; 2014 Jan 01; 63(1):23-4. PubMed ID: 24084225
    [No Abstract] [Full Text] [Related]

  • 11. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y, Kawada M, Sawanobori K, Sonoki H, Inoue K, Mizuno K, Itou T, Tabunoki Y, Tsukamoto M, Ohashi Y, Kyotani Y, Shimizu N, Fujii M, Nakamura M.
    Arzneimittelforschung; 1998 Mar 01; 48(3):219-31. PubMed ID: 9553677
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: comparative study of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium.
    Kihara Y, Inoko M, Hatakeyama N, Momose Y, Sasayama S.
    J Cardiovasc Pharmacol; 1996 Jan 01; 27(1):42-51. PubMed ID: 8656657
    [Abstract] [Full Text] [Related]

  • 13. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I.
    Med Monatsschr Pharm; 2011 May 01; 34(5):154-8. PubMed ID: 21644373
    [Abstract] [Full Text] [Related]

  • 14. Effects of flecainide on contractile force and electrophysiological parameters in cardiac muscle.
    Schulze JJ, Knops J.
    Arzneimittelforschung; 1982 May 01; 32(9):1025-9. PubMed ID: 6890819
    [Abstract] [Full Text] [Related]

  • 15. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 01; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 16. Inotropic and coronary vasodilatory actions of the K-adenosine triphosphate channel modulator nicorandil in human tissue.
    Müller-Ehmsen J, Brixius K, Hoischen S, Schwinger RH.
    J Pharmacol Exp Ther; 1996 Dec 01; 279(3):1220-8. PubMed ID: 8968344
    [Abstract] [Full Text] [Related]

  • 17. Effects of flecainide on atrial and ventricular refractoriness in rabbits in vitro and in vivo.
    Leung MW, Chan AP, So PP, Lowe GC, Guppy LJ, Walker MJ.
    Proc West Pharmacol Soc; 2004 Dec 01; 47():42-5. PubMed ID: 15633609
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN, Eschenhagen T.
    Dtsch Med Wochenschr; 2010 May 01; 135(19):971-6. PubMed ID: 20446233
    [Abstract] [Full Text] [Related]

  • 20. Ventricular preexcitation sensitive to flecainide in late stage chick embryo ECGs: 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs inotropic but not chronotropic or dromotropic responses to isoproterenol and confers resistance to flecainide.
    Fan L, Ovadia M, Friedman DM, Rifkind AB.
    Toxicol Appl Pharmacol; 2000 Jul 01; 166(1):43-50. PubMed ID: 10873717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.